The TechMed EventProgrammeAll sessionsDriving Global Change: Turning Technology into Healthcare Success Stories

Driving Global Change: Turning Technology into Healthcare Success Stories

Join us for an inspiring session on how cutting-edge technological innovations are being transformed into successful medtech innovations. This session will showcase five compelling examples of companies that originated in Twente and have scaled up to make a significant impact in the healthcare industry. From the early stages of an idea to the development of a thriving business, these success stories highlight the entrepreneurial spirit and technological expertise of the region. We will conclude with a panel discussion where industry leaders reflect on key lessons from these examples and explore future opportunities. Don’t miss this chance to gain insights into what it takes to bring groundbreaking medical technologies to life!

General information
  • Time: 13.15 - 14.30
  • Language: English
  • Room: INNOVATION STAGE (TL 1336 | Ground floor)
  • Available seats: 100

The programme

13.15 - 13.20

Welcome & Introduction
Cindy Marsman, MedTech Twente

13.20 - 13.30

Talk 1
Jeroen Wissink, Uneedle

13.30 - 13.40

Talk 2
Jasper van Weerd, Lipocoat

13.40 - 13.50 

Evidencio: a platform for medical decision support software
Tom Hueting, Evidencio

13.50 - 14.00

Holland Hybrid Heart: Turning Technology into Healthcare Success
Arie Paul van den Beukel, Hybrid Heart

14.00 - 14.30

Discussion about the lessons learned
incl all companies

14.30

Closing
Cindy Marsman, MedTech Twente

Speakers

Tom Hueting | Evidencio

Tom holds an MSc in Health Sciences and a PhD on the development, validation, and impact assessment of clinical prediction models. He has expertise in integrating predictive algorithms into clinical workflows, ensuring their compliance with regulatory standards. With a solid understanding of the EU Medical Device Regulation (MDR), he has guided software products through the regulatory process, focusing on safety and performance requirements.

Jeroen Wissink | Uneedle

Wissink graduated in 1997 from the University of Twente, specialising in micro/nanotechnology within Electrical Engineering. From 1997 to 2002, he worked with Henk Leeuwis in the microtechnology group of 3T, which formed a foundation for LioniX in 2002. He co-founded several companies focussing on Life Science applications using silicon technology from the Nanolab, including Medspray (2001), Nanomi (2004), and Uneedle (2008). As CEO of Uneedle since 2017, Wissink has been instrumental in develop

Arie Paul van den Beukel | Hybrid Heart

Professor Industrial Design at the Academy Life Science, Engineering & Design (LED) at Saxion University of Applied Sciences. 18 years of experience in research, education and development. Team of 12 researchers & developers focussing on tools and approaches for Responsible Design for the entire Product Life Cycle, ranging from early stakeholder participation, revealing barriers and enablers for innovation, anticipating counter-productive effects. rapid prototyping. Design for Health Care.

Jasper van Weerd | Lipocoat

Jasper van Weerd is a researcher at Lipocoat and is affiliated with the University of Twente. He completed his Bachelor's degree in Biomedical Engineering, followed by a Master's degree at the University of Twente, where he specialized in advanced biomaterials and drug delivery systems. At Lipocoat, Jasper plays a crucial role in developing innovative coatings that enhance the performance of medical devices. His research focuses on creating advanced surface modifications that improve biocompatibility and functionality, ultimately leading to better patient outcomes. Jasper’s work aims to address challenges in the healthcare sector by providing safer and more effective solutions for medical applications. His contributions to Lipocoat are integral to advancing the company's mission to revolutionize medical device technology through cutting-edge research and development. Jasper's commitment to innovation in biomaterials makes him a key asset to the Lipocoat team and the broader biomedical engineering community.